PMID- 28044236
OWN - NLM
STAT- MEDLINE
DCOM- 20180314
LR  - 20181113
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Print)
IS  - 0301-1623 (Linking)
VI  - 49
IP  - 5
DP  - 2017 May
TI  - Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: 
      effect of single hemodialysis session on its level in regard to type of 
      anticoagulant.
PG  - 875-879
LID - 10.1007/s11255-016-1497-3 [doi]
AB  - PURPOSE: Traditional anticoagulants used in intermittent hemodialysis (HD) are 
      unfractionated heparin (UFH) and increasingly low molecular weight heparins 
      (LMWHs). Repeated and prolonged exposure to UFH and/or LMWHs may further disturb 
      hemostasis in uremic patients. Vascular adhesion protein-1 (VAP-1) is secreted by 
      vascular smooth muscle cells, adipocytes and endothelial cells with functional 
      monoamine oxidase activity and is elevated in atherosclerosis, diabetes mellitus 
      and obesity. The aim of this study was to assess the effects of UFH and LMWHs on 
      VAP-1 concentration in HD patients. The effects on single HD session on VAP-1 
      were also evaluated as well as VAP-1 levels in regard to type of renal 
      replacement therapy. METHODS: We studied 82 hemodialyzed patients (mean age 
      63 years, dialysis vintage 59 months) and 17 patients treated by means of 
      hemodiafiltration (HDF) (mean age 59 years, HD vintage 84 months, HDF 7 months). 
      Patients were anticoagulated with enoxaparin (n = 46), dalteparin (n = 10), 
      nadroparin (n = 6) or UFH (n = 20) during their HD sessions. VAP-1 was assessed 
      using kits from BioVendor, Modrice, Czech Republic. RESULTS: Patients on HDF had 
      significantly lower VAP-1 when compared with HD patients. We found that VAP-1 
      concentration in patients dialyzed by using LMWH or UFH was similar. There was no 
      effect on HD session on VAP-1 concentration. Diabetic patients had higher serum 
      VAP-1 than non-diabetic. CONCLUSIONS: HDF is associated with lower VAP-1 levels 
      indicating less pronounced endothelial cell injury than hemodialysis. Type of 
      heparin seems to have no effect on VAP-1 levels in hemodialyzed patients. 
      However, the cross-sectional but not prospective design is a limitation of this 
      study.
FAU - Malyszko, Jolanta
AU  - Malyszko J
AD  - 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical 
      University, M. Sklodowskiej-Curie 24a, 15-276, Bialystok, Poland. 
      jolmal@poczta.onet.pl.
FAU - Koc-Zorawska, Ewa
AU  - Koc-Zorawska E
AD  - 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical 
      University, M. Sklodowskiej-Curie 24a, 15-276, Bialystok, Poland.
FAU - Kozminski, Piotr
AU  - Kozminski P
AD  - Dialysis Unit, Mlawa, Poland.
FAU - Malyszko, Jacek S
AU  - Malyszko JS
AD  - 1st Department Nephrology and Transplantology with Dialysis Unit, Medical 
      University, Bialystok, Poland.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170102
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - EC 1.4.3.21 (AOC3 protein, human)
RN  - EC 1.4.3.21 (Amine Oxidase (Copper-Containing))
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Amine Oxidase (Copper-Containing)/*metabolism
MH  - Analysis of Variance
MH  - Anticoagulants/administration & dosage
MH  - Biomarkers/metabolism
MH  - Cell Adhesion Molecules/*metabolism
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Hemodiafiltration/adverse effects/*methods
MH  - Heparin/*administration & dosage
MH  - Heparin, Low-Molecular-Weight/administration & dosage
MH  - Humans
MH  - Kidney Failure, Chronic/diagnosis/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Renal Dialysis/adverse effects/*methods/mortality
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Statistics, Nonparametric
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC5403847
OTO - NOTNLM
OT  - Anticoagulation
OT  - Hemodiafiltration
OT  - Hemodialysis
OT  - LMWH
OT  - UFH
OT  - VAP-1
COIS- The authors declare that they have no conflict of interest.
EDAT- 2017/01/04 06:00
MHDA- 2018/03/15 06:00
PMCR- 2017/01/02
CRDT- 2017/01/04 06:00
PHST- 2016/08/07 00:00 [received]
PHST- 2016/12/27 00:00 [accepted]
PHST- 2017/01/04 06:00 [pubmed]
PHST- 2018/03/15 06:00 [medline]
PHST- 2017/01/04 06:00 [entrez]
PHST- 2017/01/02 00:00 [pmc-release]
AID - 10.1007/s11255-016-1497-3 [pii]
AID - 1497 [pii]
AID - 10.1007/s11255-016-1497-3 [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2017 May;49(5):875-879. doi: 10.1007/s11255-016-1497-3. Epub 
      2017 Jan 2.